Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

[1]  S. Schulman.  Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism , 2020, Seminars in Thrombosis and Hemostasis.

[2]  H. Kwaan.  Coronavirus Disease 2019: The Role of the Fibrinolytic System from Transmission to Organ Injury and Sequelae , 2020, Seminars in Thrombosis and Hemostasis.

[3]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[4]  T. Walther,et al.  Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts , 2020, European heart journal.

[5]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[6]  Mario Plebani,et al.  Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis , 2020, Clinical chemistry and laboratory medicine.

[7]  Xiaowei Yan,et al.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.

[8]  R. McIntyre,et al.  Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series , 2020, Journal of Thrombosis and Haemostasis.

[9]  G. Lippi,et al.  ANNALS EXPRESS: Electrolyte Imbalances in Patients with Severe Coronavirus Disease 2019 (COVID-19). , 2020, Annals of clinical biochemistry.

[10]  W. Xu,et al.  Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion , 2020, Cellular & Molecular Immunology.

[11]  W. Xu,et al.  RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion , 2020, Cellular & Molecular Immunology.

[12]  G. Lippi,et al.  Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 , 2020, Mayo Clinic Proceedings.

[13]  G. Lippi,et al.  D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis , 2020, Thrombosis and Haemostasis.

[14]  J. Thachil,et al.  The versatile heparin in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[15]  D. Falci,et al.  Clinical Characteristics of Covid-19 in China. , 2020, The New England journal of medicine.

[16]  A. Chen,et al.  Clinical Characteristics of Covid-19 in China. , 2020, The New England journal of medicine.

[17]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[18]  Hongming Miao,et al.  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.

[19]  X. Bian,et al.  [A pathological report of three COVID-19 cases by minimally invasive autopsies]. , 2020, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[20]  Mario Plebani,et al.  Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis , 2020, Clinica Chimica Acta.

[21]  R. Morgan,et al.  COVID-19: the gendered impacts of the outbreak , 2020, The Lancet.

[22]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[23]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[24]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[25]  Lei Liu,et al.  Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19) , 2020 .

[26]  Jing Yuan,et al.  Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury , 2020, Science China Life Sciences.

[27]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[28]  中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组.  The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China./ 新型冠状病毒肺炎流行病学特征分析 , 2020 .

[29]  China Cdc Weekly.  The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 , 2020, China CDC weekly.

[30]  I. Henderson,et al.  Understanding Infection-Induced Thrombosis: Lessons Learned From Animal Models , 2019, Front. Immunol..

[31]  M. Rondina,et al.  The Era of Thromboinflammation: Platelets Are Dynamic Sensors and Effector Cells During Infectious Diseases , 2019, Front. Immunol..

[32]  C. Jenne,et al.  Platelet-Neutrophil Interplay: Insights Into Neutrophil Extracellular Trap (NET)-Driven Coagulation in Infection , 2019, Front. Cardiovasc. Med..

[33]  D. Casarini,et al.  Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1‐7)/MAS receptor axes in human mesangial cells , 2019, Physiological reports.

[34]  S. Jackson,et al.  Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. , 2019, Blood.

[35]  G. Lippi,et al.  Understanding the “philosophy” of laboratory hemostasis , 2018, Diagnosis.

[36]  Lisa E. Gralinski,et al.  Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis , 2018, mBio.

[37]  R. Medcalf,et al.  Haemostasis and innate immunity – a complementary relationship , 2018, British journal of haematology.

[38]  A. Canivet,et al.  TLR7 escapes X chromosome inactivation in immune cells , 2018, Science Immunology.

[39]  Bin Yang,et al.  Low-molecular-weight heparin treatment for acute lung injury / acute respiratory distress syndrome : a meta-analysis of randomized controlled trials , 2018 .

[40]  S. Bonovas,et al.  The evolving role of the renin–angiotensin system in ARDS , 2017, Critical Care.

[41]  Haibo Zhang,et al.  Recombinant human ACE2: acing out angiotensin II in ARDS therapy , 2017, Critical Care.

[42]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[43]  S. Orfanos,et al.  Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation , 2016, Respiration.

[44]  S. Massberg,et al.  Blood coagulation in immunothrombosis-At the frontline of intravascular immunity. , 2016, Seminars in immunology.

[45]  I. Jaunalksne,et al.  Activation of Coagulation and Fibrinolysis in Acute Respiratory Distress Syndrome: A Prospective Pilot Study , 2016, Front. Med..

[46]  M. Raftery,et al.  Neutrophil Extracellular Traps Go Viral , 2016, Front. Immunol..

[47]  Lei Wan,et al.  SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6 , 2016, International journal of molecular sciences.

[48]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[49]  Lesley M. Chapman,et al.  Emerging roles for platelets as immune and inflammatory cells. , 2014, Blood.

[50]  Zhongbin Chen,et al.  SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex , 2014, Protein & Cell.

[51]  N. Secher,et al.  Hypercoagulability in response to elevated body temperature and central hypovolemia. , 2013, The Journal of surgical research.

[52]  T. van der Poll,et al.  Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome , 2013, Journal of thrombosis and haemostasis : JTH.

[53]  Merlin C. Thomas,et al.  Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease , 2012, International journal of peptides.

[54]  A. Thomsen,et al.  Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus Invasion , 2012, Journal of Virology.

[55]  J. Arnal,et al.  The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling. , 2012, Blood.

[56]  R. Fogari,et al.  Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome , 2011, Hypertension Research.

[57]  N. Van Rooijen,et al.  Excessive Neutrophils and Neutrophil Extracellular Traps Contribute to Acute Lung Injury of Influenza Pneumonitis , 2011, The American Journal of Pathology.

[58]  Peter A. Ward,et al.  The complement system , 2010, Cell and Tissue Research.

[59]  Christopher D. Paddock,et al.  Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection , 2009, Journal of Virology.

[60]  Dong-Yan Jin,et al.  Severe Acute Respiratory Syndrome Coronavirus M Protein Inhibits Type I Interferon Production by Impeding the Formation of TRAF3·TANK·TBK1/IKKϵ Complex* , 2009, The Journal of Biological Chemistry.

[61]  Q. Ning,et al.  The Nucleocapsid Protein of SARS-CoV Induces Transcription of hfgl2 Prothrombinase Gene Dependent on C/EBP Alpha , 2008, Journal of biochemistry.

[62]  Ling Liu,et al.  Effect of Fluvastatin and Valsartan, Alone and in Combination, on Postprandial Vascular Inflammation and Fibrinolytic Activity in Patients With Essential Hypertension , 2007, Journal of cardiovascular pharmacology.

[63]  Yan Bao,et al.  Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. , 2007, Journal of biochemistry and molecular biology.

[64]  M. McNutt,et al.  Molecular Pathology in the Lungs of Severe Acute Respiratory Syndrome Patients , 2007, The American Journal of Pathology.

[65]  H. Hackstein,et al.  TLR7 Ligands Induce Higher IFN-α Production in Females1 , 2006, The Journal of Immunology.

[66]  Ho-Ming Su,et al.  Lercanidipine and Losartan Effects on Blood Pressure and Fibrinolytic Parameters , 2006, The Kaohsiung journal of medical sciences.

[67]  D. Vaughan,et al.  Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. , 2006, Kidney international.

[68]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[69]  P. Walsh.  Platelet coagulation-protein interactions. , 2004, Seminars in thrombosis and hemostasis.

[70]  H. Hauner,et al.  Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension , 2004, Diabetes, obesity & metabolism.

[71]  D. Vaughan,et al.  Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. , 2003, The Journal of clinical endocrinology and metabolism.

[72]  M. Horie,et al.  Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. , 2003, Journal of the American College of Cardiology.

[73]  M. Dinçer,et al.  Effect of Spironolactone on Impaired Fibrinolysis of Hypertensive Patients , 2002, Kidney and Blood Pressure Research.

[74]  D. Vaughan,et al.  Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. , 2002, The Journal of clinical endocrinology and metabolism.

[75]  M. Kinoshita,et al.  Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. , 2001, Journal of the American College of Cardiology.

[76]  H. Hauner,et al.  Angiotensin II and Its Metabolites Stimulate PAI-1 Protein Release From Human Adipocytes in Primary Culture , 2001, Hypertension.

[77]  D. Vaughan,et al.  Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. , 2000, Kidney international.

[78]  D. Vaughan,et al.  Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo1 , 2000 .

[79]  D. Vaughan,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 Production* , 1999 .

[80]  D. Vaughan,et al.  Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. , 1998, Hypertension.

[81]  M. Pfeffer,et al.  Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. , 1997, Circulation.

[82]  D. Vaughan,et al.  Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin , 1997, Thrombosis and Haemostasis.

[83]  D. Harrison,et al.  Reversing endothelial dysfunction with ACE inhibitors. A new trend. , 1996, Circulation.

[84]  D. Vaughan,et al.  Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. , 1995, The Journal of clinical investigation.